{"name":"Evofem Biosciences","slug":"evofem","ticker":"EVFM","exchange":"NASDAQ","domain":"evofem.com","description":"Evofem Biosciences is a biopharmaceutical company focused on developing and commercializing innovative solutions for women's health. The company's lead product, Phexxi, is a non-hormonal, on-demand contraceptive gel. Evofem Biosciences is positioned to address unmet needs in women's reproductive health.","hq":"San Diego, CA","founded":0,"employees":"","ceo":"Saundra Pelletier","sector":"Women\\","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$35M","metrics":{"revenue":42000000,"revenueGrowth":104.2,"grossMargin":0,"rdSpend":1845000,"netIncome":391000,"cash":20274000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2022"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Evofem Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Evofem Biosciences reported its fourth quarter and full year 2023 financial results, with revenue of $14.4 million for the year.","drugName":"","sentiment":"neutral"},{"date":"2023-06-29","type":"deal","headline":"Evofem Biosciences Announces Exclusive Distribution Agreement with Ferring Pharmaceuticals for Phexxi in the United States","summary":"Evofem Biosciences announced an exclusive distribution agreement with Ferring Pharmaceuticals for Phexxi in the United States.","drugName":"","sentiment":"positive"},{"date":"2022-12-20","type":"regulatory","headline":"FDA Approves Phexxi (lactic acid, citric acid, and potassium bitartrate) for the Prevention of Pregnancy","summary":"The FDA approved Phexxi for the prevention of pregnancy.","drugName":"","sentiment":"positive"}],"realNews":[{"date":"2026-03-19","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-11","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-11","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-01-12","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-11-26","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgJBVV95cUxQdUJGZS0tU1dDaGJILTZiWFVsYTBxNnFacnFzLUNpNWYtb09najdXcWVGdGtwdHZwandIRnZCYVhDcHhvb0ZIRWFXdXlXcGpCOElSb29EMzUyY3pPdVFfaWQ1ckJCSDZQV3lfNlNOSUJwNU1ZbEtBT2hBZXlDRHdGWFgweGN4aGxXTEFrVjVIWmJWVElyOGpjcDhUVWJzMFVveVc4U3g2UGI0b2NDTFh5aWJpd2diajNCRmx0V2t4a2hwcHloUWtGZE1xelBzR29waXRGd2NUell2QjN3VXhkUVdtbXpva19ocHVJSE03OEVXaFlYVFRwZVlycktTSmpPTVhUc0FUcHhNWTNPMEYtUkY1ei1lMUl2UFE?oc=5","date":"2025-11-21","type":"pipeline","source":"PR Newswire","summary":"Favorable Pricing Certificates Issued for Evofem's PHEXX by Emirates Drug Establishment are Launching Step for Commercialization in UAE - PR Newswire","headline":"Favorable Pricing Certificates Issued for Evofem's PHEXX by Emirates Drug Establishment are Launching Step for Commercia","sentiment":"neutral"},{"date":"2025-11-13","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-11-13","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2025-10-20","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-10-17","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-08-26","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-08-14","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2025-08-14","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxOT0s5eW1wMUpVeE1RUW5TWVpBNENYUU9zMlc4dmhmeFMyUnRUcTVRY05RdllRN29uWnhKNlUzUVFLdTBTSGJzRndjeWlVejZtek9rTDdjVW5RNXpxaHZuZUhfVFpUd2ZJNXNYWmFNZTI4akRZY0RuTV9UTmN3SDZTQWRILWxiNXN2bUNUeg?oc=5","date":"2025-07-09","type":"pipeline","source":"San Diego Business Journal","summary":"Evofem Eying Middle East Markets - San Diego Business Journal","headline":"Evofem Eying Middle East Markets","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5AFBVV95cUxOQXZWMkV0bXJkWWpLbVFrV2tFTzN1Y1lsd3FQYzVkcWlzbWlING1rRmxBOUVJOHBrR21EYTBkajNGbG9mNnJ3TDh1VGl3ZlpkZ0V5RExUNWZ3RUtkOVExQ1dPeXFjWmZzSWhCTHY5TG5kNkdranVqb3VmN2dCN05XMy1pU1hVRmlONDAtdC1XTkw2SFJtYktEQWdzd3ZDS3BubWg2NjBNcTZjUTVrNXVxUTM5N2l1akpuMDlqT0k1akhSRmxqbzJxdE1VQlF3MlJuRFhNTzQ4SEJwZ19oOFdrN3dXSUk?oc=5","date":"2025-06-23","type":"regulatory","source":"PR Newswire","summary":"Evofem's PHEXXI Submitted for Marketing Approval in United Arab Emirates by Pharma 1 Drug Store - PR Newswire","headline":"Evofem's PHEXXI Submitted for Marketing Approval in United Arab Emirates by Pharma 1 Drug Store","sentiment":"positive"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":["Takeda Pharmaceutical Company Limited","Bayer AG","Merck & Co., Inc."],"therapeuticFocus":["Women's Health","Reproductive Health"],"financials":{"source":"sec_edgar+yahoo","revenue":16837000,"revenuePeriod":"2022-12-31","revenueHistory":[{"value":16837000,"period":"2022-12-31"},{"value":8244000,"period":"2021-12-31"},{"value":8244000,"period":"2021-12-31"},{"value":446000,"period":"2020-12-31"},{"value":446000,"period":"2020-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":1845000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":391000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":20274000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}